

# Genetic Resistance to Scrapie Infection in Experimentally Challenged Goats

Caroline Lacroux,<sup>a</sup> Cécile Perrin-Chauvineau,<sup>b</sup> Fabien Corbière,<sup>a</sup> Naima Aron,<sup>a</sup> Patricia Aguilar-Calvo,<sup>c</sup> Juan Maria Torres,<sup>c</sup> Pierrette Costes,<sup>a</sup> Isabelle Brémaud,<sup>b</sup> Séverine Lukan,<sup>a</sup> François Schelcher,<sup>a</sup> Francis Barillet,<sup>d</sup> Olivier Andréoletti<sup>a</sup>

INRA, UMR 1225, Interactions Hôtes Agents Pathogènes, Ecole Nationale Vétérinaire de Toulouse, Toulouse, France<sup>a</sup>; AFSSA-Niort, Laboratoire d'Études et de Recherches Caprines, Niort, France<sup>b</sup>; CISA-INIA, Madrid, Spain<sup>c</sup>; INRA, UR 631, Station d'Amélioration Génétique des Animaux, Castanet-Tolosan, France<sup>d</sup>

In goats, several field studies have identified coding mutations of the gene encoding the prion protein (I/M<sub>142</sub>, N/D<sub>146</sub>, S/D<sub>146</sub>, R/Q<sub>211</sub>, and Q/K<sub>222</sub>) that are associated with a lower risk of developing classical scrapie. However, the data related to the levels of resistance to transmissible spongiform encephalopathies (TSEs) of these different *PRNP* gene mutations are still considered insufficient for developing large-scale genetic selection against scrapie in this species. In this study, we inoculated wild-type (WT) *PRNP* (I<sub>142</sub>R<sub>154</sub>R<sub>211</sub>Q<sub>222</sub>) goats and homozygous and/or heterozygous I/M<sub>142</sub>, R/H<sub>154</sub>, R/Q<sub>211</sub>, and Q/K<sub>222</sub> goats with a goat natural scrapie isolate by either the oral or the intracerebral (i.c.) route. Our results indicate that the I/M<sub>142</sub> *PRNP* polymorphism does not provide substantial resistance to scrapie infection following intracerebral or oral inoculation. They also demonstrate that H<sub>154</sub>, Q<sub>211</sub>, and K<sub>222</sub> *PRNP* allele carriers are all resistant to scrapie infection following oral exposure. However, in comparison to WT animals, the H<sub>154</sub> and Q<sub>211</sub> allele carriers displayed only moderate increases in the incubation period following i.c. challenge. After i.c. challenge, heterozygous K<sub>222</sub> and a small proportion of homozygous K<sub>222</sub> goats also developed the disease, but with incubation periods that were 4 to 5 times longer than those in WT animals. These results support the contention that the K<sub>222</sub> goat prion protein variant provides a strong but not absolutely protective effect against classical scrapie.

Transmissible spongiform encephalopathies (TSEs), or prion diseases, are fatal neurodegenerative disorders occurring in small ruminants (scrapie), cattle (bovine spongiform encephalopathy [BSE]), and humans (Creutzfeldt-Jakob disease [CJD]). The key event in TSEs is the conversion of a normal cellular protein (PrP<sup>C</sup>) into an abnormal isoform (PrP<sup>Sc</sup>) which accumulates in tissues in infected individuals. According to the prion concept, abnormal PrP is the causative agent of TSEs (1).

In sheep, susceptibility to TSEs is strongly modulated by polymorphisms of the prion protein gene (*PRNP*) and the nature of the prion disease agent (strain) (2). The A<sub>136</sub>R<sub>154</sub>R<sub>171</sub> allele is associated with a highly protective effect against natural or experimental infection with classical scrapie and BSE agents, while the V<sub>136</sub>R<sub>154</sub>Q<sub>171</sub> allele and the wild-type (WT) A<sub>136</sub>R<sub>154</sub>Q<sub>171</sub> allele are associated with susceptibility (3, 4). However, in sheep, the ARR allele does not provide any particular protection against atypical scrapie, whereas the R/H<sub>154</sub> or L/F<sub>141</sub> amino acid substitution is associated with an increased risk of occurrence of this TSE (5–8).

At the European level, the selection of ARR allele carriers was successfully applied for controlling and eradicating classical scrapie in infected sheep flocks (9). Large-scale selection programs were also implemented at the population level. They aimed to increase the frequency of the ARR allele in the general population, making it less favorable to TSE agent circulation and spreading. This “breeding for resistance” policy, in combination with other eradication measures, resulted in a significant reduction of the prevalence of classical scrapie in populations where it was comprehensively applied (10–12).

In goats, several field studies have identified coding mutations of the *PRNP* gene that are associated with a lower risk of developing classical scrapie, namely, the I/M<sub>142</sub>, N/D<sub>146</sub> and S<sub>146</sub>, R/Q<sub>211</sub>, and Q/K<sub>222</sub> alleles (13–18). However, the low frequencies of these alleles in the goat population limit the possibility of reaching an unequivocal conclusion about the resistance/susceptibility to in-

fection associated with these different *PRNP* genotypes (2, 13, 18). In this context, experimental TSE inoculation of goats is a straightforward and robust approach to better assess the levels of resistance associated with certain *PRNP* polymorphisms in this species (19, 20).

In this study, we inoculated wild-type goats and homozygous and/or heterozygous I/M<sub>142</sub>, R/H<sub>154</sub>, R/Q<sub>211</sub>, and Q/K<sub>222</sub> goats with a goat natural scrapie isolate, by either the intracerebral (i.c.) or the oral route, in order to characterize their relative resistances/susceptibilities to infection.

## MATERIALS AND METHODS

**Ethics statement.** All animal experiments were performed in compliance with institutional and French national guidelines, in accordance with European Community Council Directive 86/609/EEC. The experimental protocol was approved by the INRA Toulouse/ENVN ethics committee.

**Scrapie inoculum.** The inoculum was derived from a single natural scrapie field case (clinical) in a 3.5-year-old goat with the wild-type *PRNP* genotype. This animal was necropsied under TSE-sterile conditions, and its central nervous system (CNS; brain and spinal cord) was used to prepare a 10% tissue homogenate in 5% glucose. The stock homogenate was aliquoted and stored at –80°C.

**Experimental animal production.** Goat kids intended to be used in the experiment were produced by direct mating of *PRNP*-sequenced Alpine and Saanen female goats and bucks. Parents were selected from

Received 1 October 2013 Accepted 20 November 2013

Published ahead of print 27 November 2013

Editor: B. W. Caughey

Address correspondence to Olivier Andréoletti, o.andreoletti@envt.fr.

C.L. and C.P.-C. contributed equally to this article.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.

doi:10.1128/JVI.02872-13

three herds that are managed by the French National Agronomic Institute (INRA). Selection was based on the *PRNP* polymorphisms at codons 142 (I/M), 154 (R/H), 211 (R/Q), and 222 (Q/K), which were identified by previous studies as influencing susceptibility to natural scrapie (14, 18, 21). Animals were then naturally mated to produce the goats used for experimental inoculation. Exon 3 of the *PRNP* gene of each goat kid was sequenced as previously described (22).

**Goat oral challenge experiments.** For the oral challenge experiments, gravid goats were relocated to ANSES Niort A2 facilities. Within 48 h after birth, each goat kid received 1.5 g brain-equivalent material through natural suckling (1% diluted stock inoculum in 5% glucose). A second inoculation (same material and route) was performed at the age of 30 days. Considering (i) the logistic constraints (housing of goats and goat kids) and (ii) the fact that the parent goats were heterozygous only for the alleles of interest, the oral inoculation of goat kids that would have been homozygous for the mutated *PRNP* alleles was not feasible in the framework of this experiment.

Two separate oral inoculation experiments were performed. The first one aimed at establishing the PrP<sup>Sc</sup> dissemination scheme and kinetics in animals with the wild-type *PRNP* genotype. For that purpose, 3 or 4 animals were culled at 30, 90, 120, 360, 540, and 940 days postinoculation (dpi). A last group of animals ( $n = 4$ ) was kept until the occurrence of clinical signs.

The second experiment aimed at establishing the relative susceptibilities of goats harboring various genotypes to scrapie following oral exposure. WT and heterozygous I/M<sub>142</sub>, R/Q<sub>211</sub>, and Q/K<sub>222</sub> animals were orally challenged using the same isolate as in the first experiment and were culled at 120, 360, 760, and 1,040 dpi. Five animals of each genotype were killed at each of the different time points.

In addition, a group of animals from each of these genotypes and a group ( $n = 6$ ) of heterozygous R/H<sub>154</sub> animals that had also been challenged orally were kept alive for establishment of the incubation period. Because of space constraints in the animal facilities, it was not possible to challenge a sufficient number of R/H<sub>154</sub> *PRNP* allele carriers to complete the time point experiment (see below).

**Goat intracerebral challenge.** After weaning, goat kids selected by genotype were transported to UMR INRA ENVT A2 animal facilities for i.c. inoculation. When the animals were 6 months of age, they were anesthetized (ketamine plus diazepam [Valium]), and 400  $\mu$ l of the stock inoculum was injected into the temporal cortex.

**Clinical monitoring and sample collection.** Inoculated goats were clinically monitored on a daily basis. The animals that developed TSE were euthanized if they exhibited locomotor signs that impaired their feeding capacity. Animals that developed intercurrent health problems were treated by qualified veterinarians and euthanized if the condition was not curable.

Dead animals were systematically necropsied, and the CNS and a variety of lymphoid (mesenteric lymph nodes, tonsils, prescapular lymph nodes, and Peyer's patches) and nonlymphoid tissues were collected (Table 1). Half of the samples were formalin fixed, while the other half were stored frozen ( $-20^{\circ}\text{C}$ ).

**PrP<sup>Sc</sup> IHC and PrP<sup>res</sup> enzyme-linked immunosorbent assay (ELISA) detection.** PrP<sup>Sc</sup> immunohistochemistry (IHC) detection was performed as described by Lacroux et al., using the 8G8 antibody, raised against a human recombinant PrP protein and specifically recognizing amino acids 95 to 108 (SQWNKP) of the PrP protein (23).

**WB of abnormal PrP.** Proteinase K (PK)-resistant abnormal PrP (PrP<sup>res</sup>) extraction and Western blotting (WB) were performed as previously described (24), using a commercial extraction kit (Bio-Rad, France). PrP immunodetection was performed using monoclonal antibody Sha31 (0.06  $\mu$ g per ml) (YEDRYRE epitope [amino acids 145 to 152]) or 12B2 (4  $\mu$ g/ml) (WGQGG epitope [amino acids 93 to 97]) (25).

For glycoprofiling of PrP<sup>res</sup>, the signal volume and relative percentage associated with each band were established using Quantity One software

(Bio-Rad) following immunoblotting. For each sample, three independent measures were determined for three different gels.

## RESULTS

**Oral challenge in goats.** Our first oral challenge experiment in goats was designed to establish the scheme and kinetics of PrP<sup>Sc</sup> dissemination in the tissues of WT *PRNP* animals. For that purpose, goat kids obtained by natural mating of WT *PRNP* goats and bucks were orally challenged within the first 48 h following birth. Groups of these animals were culled at different time points after inoculation (Table 1). PrP<sup>Sc</sup> accumulation was first observed in the gut-associated lymphoid tissue (Peyer's patches) of animals, at more than 180 dpi. As already described for sheep, PrP<sup>Sc</sup> progressively spread to all lymphoid organs before becoming detectable (between 180 and 360 dpi) in the enteric nervous system (ENS) and, later (between 540 and 940 dpi), in the central nervous system (26).

On the basis of these results, a second oral challenge experiment was designed. The goal of this experiment was to characterize the impact of the investigated polymorphisms on the susceptibility and PrP<sup>Sc</sup> dissemination in the tissues of orally exposed animals. Groups of wild-type animals and heterozygous I/M<sub>142</sub>, R/Q<sub>211</sub>, and Q/K<sub>222</sub> animals were produced by natural mating and orally challenged using the same procedure and scrapie isolate as in the first experiment.

In the second experiment, the PrP<sup>Sc</sup> dissemination scheme observed in WT animals was consistent with the results of the first experiment (Table 2). No PrP<sup>Sc</sup> deposition was observed in the tissues collected from goats killed at 120 dpi. At 360 dpi, significant PrP<sup>Sc</sup> deposition was observed in various lymphoid tissues (Peyer's patches, mesenteric lymph nodes, and tonsils) of some of the challenged individuals. PrP<sup>Sc</sup> deposition was observed in ENS, CNS, and peripheral nervous tissues and skeletal muscles in four of the five animals culled at 760 dpi.

In the orally challenged heterozygous I/M<sub>142</sub> animals, a similar but slightly delayed PrP<sup>Sc</sup> accumulation scheme was observed; PrP<sup>Sc</sup> was first detected in the gut-associated lymphoid tissue (Peyer's patches) at 360 dpi, but it was only detected at 1,040 dpi in the CNS (Table 2).

No PrP<sup>Sc</sup> was observed in any of the tissues collected from the heterozygous R/Q<sub>211</sub> and Q/K<sub>222</sub> animals that had been orally challenged and killed at the different time points (5 animals per genotype per time point), and none of the animals bearing these genotypes had developed a clinical TSE at  $>2,500$  dpi.

In both oral challenge experiments, groups of animals harboring the different *PRNP* genotypes (I/M<sub>142</sub>, R/Q<sub>211</sub>, and Q/K<sub>222</sub>) were kept alive and clinically monitored for TSE development (Table 3). Similarly, a group of heterozygous R/H<sub>154</sub> animals ( $n = 6$ ) that had been orally challenged with the same inoculum was also monitored.

In WT goats, incubation periods in the first ( $n = 4$ ) and second ( $n = 5$ ) experiments were not different. All the challenged I/M<sub>142</sub> goats ( $n = 4$ ) also developed clinical TSEs, but with a slightly longer incubation period ( $1,490 \pm 126$  dpi) than that in WT animals ( $1,141 \pm 93$  dpi). For both genotypes, affected animals showed PrP<sup>Sc</sup> deposition in CNS and lymphoid tissues (Table 2).

After more than 2,500 days of incubation, none of the orally inoculated heterozygous R/H<sub>154</sub>, R/Q<sub>211</sub>, and Q/K<sub>222</sub> animals had developed a clinical TSE. Some of the heterozygous R/H<sub>154</sub> ( $n = 3$ ) or Q/K<sub>222</sub> ( $n = 2$ ) goats and one homozygous K/K<sub>222</sub> animal died

TABLE 1 PrP<sup>Sc</sup> detection in tissues of WT PRNP goats orally challenged with scrapie agent and sequentially killed

Organ <sup>a</sup>	30 dpi			90 dpi			180 dpi			360 dpi			540 dpi			940 dpi		
	No. of positive individuals/no. of animals tested <sup>b</sup>	PrP <sup>Sc</sup> label intensity <sup>c</sup>	No. of positive individuals/no. of animals tested <sup>b</sup>	No. of positive individuals/no. of animals tested <sup>b</sup>	PrP <sup>Sc</sup> label intensity <sup>c</sup>	No. of positive individuals/no. of animals tested <sup>b</sup>	No. of positive individuals/no. of animals tested <sup>b</sup>	PrP <sup>Sc</sup> label intensity <sup>c</sup>	No. of positive individuals/no. of animals tested <sup>b</sup>	PrP <sup>Sc</sup> label intensity <sup>c</sup>	No. of positive individuals/no. of animals tested <sup>b</sup>	No. of positive individuals/no. of animals tested <sup>b</sup>	PrP <sup>Sc</sup> label intensity <sup>c</sup>	No. of positive individuals/no. of animals tested <sup>b</sup>	PrP <sup>Sc</sup> label intensity <sup>c</sup>	No. of positive individuals/no. of animals tested <sup>b</sup>	PrP <sup>Sc</sup> label intensity <sup>c</sup>	
Obex	0/3	-	0/4	0/3	-	0/3	0/4	-	0/3	0/4	0/4	0/4	-	4/4	-	4/4	+ /+++	
Spinal cord (cervical)	ND	-	ND	ND	-	ND	ND	-	0/3	0/4	0/4	0/4	-	4/4	-	4/4	+ /+++	
Spinal cord (thoracic)	ND	-	ND	ND	-	ND	ND	-	0/3	0/4	0/4	0/4	-	4/4	-	4/4	+ /+++	
Tonsil	0/3	-	0/4	0/3	-	0/3	0/4	-	1/3 (a)	2/4 (a, b)	2/4 (a, b)	2/4 (a, b)	+	4/4	+	4/4	+++	
Parotid LN	0/3	-	0/4	0/3	-	0/3	0/4	-	1/3 (a)	3/4 (a to c)	3/4 (a to c)	3/4 (a to c)	+	4/4	+	4/4	+++	
Retropharyngeal LN	0/3	-	0/4	0/3	-	0/3	0/4	-	2/3 (a, b)	3/4 (a to c)	3/4 (a to c)	3/4 (a to c)	+	4/4	+	4/4	+++	
Spleen	0/3	-	0/4	0/3	-	0/3	0/4	-	0/3	1/4 (a)	1/4 (a)	1/4 (a)	-	4/4	+	4/4	+++	
Duodenal PP	0/3	-	0/4	0/3	-	0/3	0/4	-	3/3	4/4	4/4	4/4	+	4/4	+	4/4	+++	
Jejunum PP	0/3	-	0/4	2/3 (a, b)	-	2/3 (a, b)	0/4	-	3/3	4/4	4/4	4/4	+	4/4	+	4/4	+++	
Ileal PP	0/3	-	0/4	2/3 (a, b)	-	2/3 (a, b)	0/4	-	3/3	4/4	4/4	4/4	+	4/4	+	4/4	+++	
Cecal PP	0/3	-	0/4	0/3	-	0/3	0/4	-	1/3 (a)	4/4	4/4	4/4	+	4/4	+	4/4	+++	
Jejunum MLN	0/3	-	0/4	2/3 (a, b)	-	2/3 (a, b)	0/4	-	3/3	4/4	4/4	4/4	+	4/4	+	4/4	+++	
Ileal MLN	0/3	-	0/4	1/3 (a)	-	1/3 (a)	0/4	-	3/3	4/4	4/4	4/4	+	4/4	+	4/4	+++	
Mediastinal LN	0/3	-	0/4	0/3	-	0/3	0/4	-	1/3 (a)	2/4 (a, b)	2/4 (a, b)	2/4 (a, b)	+	4/4	+	4/4	+++	
Prescapular LN	0/3	-	0/4	0/3	-	0/3	0/4	-	1/3 (a)	4/4	4/4	4/4	+	4/4	+	4/4	+++	
Retrohepatic LN	0/3	-	0/4	0/3	-	0/3	0/4	-	1/3 (a)	4/4	4/4	4/4	+	4/4	+	4/4	+++	
Duodenum (ENS)	0/3	-	0/4	0/3	-	0/3	0/4	-	1/3 (a)	4/4	4/4	4/4	+	4/4	+	4/4	+++	
Jejunum (ENS)	0/3	-	0/4	0/3	-	0/3	0/4	-	1/3 (a)	4/4	4/4	4/4	+	4/4	+	4/4	+++	
Ileum (ENS)	0/3	-	0/4	0/3	-	0/3	0/4	-	1/3 (a)	4/4	4/4	4/4	+	4/4	+	4/4	+++	
Cecum (ENS)	0/3	-	0/4	0/3	-	0/3	0/4	-	0/3	3/4 (a to c)	3/4 (a to c)	3/4 (a to c)	-	4/4	+	4/4	+++	
Colon (ENS)	0/3	-	0/4	0/3	-	0/3	0/4	-	0/3	3/4 (a to c)	3/4 (a to c)	3/4 (a to c)	-	4/4	+	4/4	+++	
Sciatic nerve	0/3	-	0/3	0/3	-	0/3	0/3	-	0/3	0/4	0/4	0/4	-	4/4	-	4/4	+	
Brachial nerve	0/3	-	0/3	0/3	-	0/3	0/3	-	0/3	0/4	0/4	0/4	-	4/4	-	4/4	+	
External ocular muscle	0/3	-	0/3	0/3	-	0/3	0/3	-	0/3	0/4	0/4	0/4	-	4/4	-	4/4	+	

<sup>a</sup> For the spinal cord, cervical (C3-C4), thoracic (Th7-Th8), and lumbar (L3-L4) segments were analyzed. LN, lymph nodes; PP, Peyer's patches; MLN, mesenteric lymph nodes; ENS, enteric nervous system.

<sup>b</sup> At each time point, the positive goats are identified arbitrarily by the letters a to d. ND, no data.

<sup>c</sup> PrP<sup>Sc</sup> labeling intensities are indicated as follows (as previously described [26]): -, negative; +, minimal to slight; ++, moderate; and +++, strong.

TABLE 2 PrP<sup>Sc</sup> detection in tissues of WT and I/M<sub>142</sub> PRNP goats orally challenged with scrapie agent and sequentially killed

Organ <sup>a</sup>	120 dpi			360 dpi			760 dpi			1,040 dpi		
	WT		I/M <sub>142</sub>	WT		I/M <sub>142</sub>	WT		I/M <sub>142</sub>	WT		I/M <sub>142</sub>
	No. of positive individuals/ no. of animals tested <sup>b</sup>	PrP <sup>Sc</sup> label intensity <sup>c</sup>	No. of positive individuals/ no. of animals tested <sup>b</sup>	PrP <sup>Sc</sup> label intensity <sup>c</sup>	No. of positive individuals/ no. of animals tested <sup>b</sup>	PrP <sup>Sc</sup> label intensity <sup>c</sup>	No. of positive individuals/ no. of animals tested <sup>b</sup>	PrP <sup>Sc</sup> label intensity <sup>c</sup>	No. of positive individuals/ no. of animals tested <sup>b</sup>	PrP <sup>Sc</sup> label intensity <sup>c</sup>	No. of positive individuals/ no. of animals tested <sup>b</sup>	PrP <sup>Sc</sup> label intensity <sup>c</sup>
Obex	0/5	—	0/5	—	4/5 (a to d)	+ / + + +	0/5	—	5/5	—	2/5 (a, b)	+ / + +
Spinal cord (cervical)	ND	—	0/5	—	1/5 (a)	+	0/5	—	4/5 (a to d)	+ / + + +	0/5	—
Spinal cord (thoracic)	ND	—	0/5	—	1/5 (a)	+	0/5	—	5/5	—	0/5	—
Tonsil	0/5	—	0/5	—	1/5 (a)	+	0/5	—	5/5	—	0/5	—
Parotid LN	0/5	—	0/5	—	4/5 (a to d)	+ / + + +	5/5	—	5/5	—	3/5 (a to c)	+ / + + +
Retropharyngeal LN	0/5	—	0/5	—	4/5 (a to d)	+ / + + +	5/5	—	5/5	—	3/5 (a to c)	+ / + + +
Spleen	0/5	—	0/5	—	4/5 (a to d)	+ / + + +	2/5 (a, b)	+	5/5	—	2/5 (a, b)	+
Duodenal PP	0/5	—	0/5	—	1/5 (a)	+	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Jejunal PP	0/5	—	0/5	—	0/5	—	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Ileal PP	0/5	—	0/5	—	2/5 (a, b)	+	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Cecal PP	0/5	—	0/5	—	0/5	—	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Jejunal MLN	0/5	—	0/5	—	1/5 (a)	+	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Ileal MLN	0/5	—	0/5	—	1/5 (a)	+	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Prescapular LN	0/5	—	0/5	—	2/5 (a, b)	+	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Mediastinal LN	0/5	—	0/5	—	0/5	—	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Retropharyngeal LN	0/5	—	0/5	—	0/5	—	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Duodenum (ENS)	0/5	—	0/5	—	0/5	—	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Jejunum (ENS)	0/5	—	0/5	—	0/5	—	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Ileum (ENS)	0/5	—	0/5	—	0/5	—	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Cecum (ENS)	0/5	—	0/5	—	0/5	—	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Colon (ENS)	0/5	—	0/5	—	0/5	—	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Sciatic nerve	0/5	—	0/5	—	0/5	—	0/5	—	5/5	—	4/5 (a to d)	+ / + + + +
Brachial nerve	0/5	—	0/5	—	1/5 (a)	+	0/5	—	5/5	—	0/5	—
External ocular muscle	0/5	—	0/5	—	1/5 (a)	+	0/5	—	5/5	—	0/5	—

<sup>a</sup> For the spinal cord, cervical (C3-C4), thoracic (Th7-Th8), and lumbar (L3-L4) segments were analyzed. LN, lymph nodes; PP, Peyer's patches; MLN, mesenteric lymph nodes; ENS, enteric nervous system.

<sup>b</sup> At each time point, the positive goats are identified arbitrarily by the letters a to d. ND, no data.

<sup>c</sup> PrP<sup>Sc</sup> labeling intensities are indicated as follows (as previously described [26]): —, negative; +, minimal to slight; ++, moderate; and + + +, strong.

**TABLE 3** Scrapie incubation periods and PrP<sup>Sc</sup> deposition in central nervous system and lymphoid tissues in goats inoculated by the oral route, shown according to genotypes at codons 142, 154, 211, 222, and 240 of the *PRNP* gene

Genotype	No. of scrapie-affected animals/total no. of animals	Scrapie incubation period (dpi) (mean ± SD)	Death from intercurrent disease		PrP <sup>Sc</sup> accumulation (no. of goats/total no. examined)	
			No. of goats/total no. in group <sup>a</sup>	Time to death (dpi)	CNS	Lymphoid tissues <sup>b</sup>
IRRQS/IRRQS (wild type)	9/9	1,141 ± 93			9/9	9/9
M <sub>142</sub> RQP <sub>240</sub> /IRRQS	4/4	1,490 ± 126			4/4	4/4
IH <sub>154</sub> RQS/IRRQS	0/6		3/6	966, 1,002, 1,853	0/3	0/3
IRQ <sub>211</sub> QS/IRRQS	0/5		2/5	1,234, 1,678	0/2	0/2
IRRK <sub>222</sub> S/IRRQS	0/5		1/5	1,815	0/1	0/1

<sup>a</sup> Animals that were still alive were at <2,500 days postinoculation at the time of writing.

<sup>b</sup> Tonsils, prescapular lymph nodes, ileal/jejunal Peyer's patches, and mesenteric lymph nodes.

from intercurrent disease (Table 3). In these orally challenged animals, none of the investigated tissues (lymphoid organs and CNS) displayed any detectable PrP<sup>Sc</sup> deposition.

Together, these findings support the contention that R/H<sub>154</sub>, R/Q<sub>211</sub>, and Q/K<sub>222</sub> PrP mutant alleles have a strong protective effect against scrapie infection following oral exposure.

**Intracerebral challenge in goats.** To further assess the resistance to scrapie associated with the I/M<sub>142</sub>, R/H<sub>154</sub>, R/Q<sub>211</sub>, and Q/K<sub>222</sub> PrP alleles, groups of heterozygous and homozygous animals were inoculated intracerebrally with the same isolate as that used for oral challenge (Table 4). As expected, all the intracerebrally inoculated WT goats developed clinical TSEs. In those animals, PrP<sup>Sc</sup> deposits were observed in both the central nervous system and lymphoid tissues.

In contrast to the results of the oral challenge experiment, the heterozygous I/M<sub>142</sub>, R/H<sub>154</sub>, and R/Q<sub>211</sub> animals, and also homozygous Q/Q<sub>211</sub> animals, developed clinical TSEs. Strikingly, the heterozygous R/Q<sub>211</sub> individuals displayed a longer incubation period than the homozygous Q/Q<sub>211</sub> animals. PrP<sup>Sc</sup> deposition was observed in the lymphoid tissues of the heterozygous I/M<sub>142</sub> and homozygous Q/Q<sub>211</sub> animals. No or limited PrP<sup>Sc</sup> accumulation was observed in lymphoid tissues from R/H<sub>154</sub> and R/Q<sub>211</sub> animals. With the Sha31 antibody, the PrP<sup>res</sup> WB patterns observed for the brains of all the scrapie-affected R/H<sub>154</sub> individuals were identical and differed strikingly from those observed for in-

dividuals bearing other *PRNP* genotypes (Fig. 1): the PrP<sup>res</sup> bands displayed apparently lower molecular weights. Immunoblots probed with the 12B2 antibody indicated that in H/R<sub>154</sub> goats, PK digestion resulted in an N-terminal cleavage of PrP<sup>res</sup> (amino acids 93 to 97) that differed from the case in the other genotype groups.

Among the i.c. challenged heterozygous Q/K<sub>222</sub> goats, three animals died of intercurrent disease, at 568, 898, and 1,062 dpi. No PrP<sup>Sc</sup> accumulation was observed in any of the investigated tissues from these goats. However, the two remaining animals developed clinical TSEs, after 1,980 and 2,134 dpi, and in those two individuals, PrP<sup>Sc</sup> deposits were observed (by IHC and WB) in the central nervous system but not in lymphoid organs.

One of the five i.c. challenged homozygous K<sub>222</sub> animals developed a clinical TSE and was euthanized after 2,101 dpi. Abnormal PrP deposition was detected (by IHC and WB) in the central nervous system but not in the lymphoid tissues. The four remaining K/K<sub>222</sub> animals were still apparently healthy at the time of writing (>2,400 dpi).

Using the Sha31 antibody, Q/K<sub>222</sub>- and K/K<sub>222</sub>-positive individuals displayed similar PrP<sup>res</sup> glycoform ratios. The PrP<sup>res</sup> glycoprofiles of these individuals displayed dominant monoglycosylated bands which clearly differed from the patterns observed for the goats with other genotypes (Fig. 2).

More generally, the presence of apparently different PrP<sup>res</sup> WB


**TABLE 4** Scrapie incubation periods and PrP<sup>Sc</sup> deposition in central nervous system and lymphoid tissues in intracerebrally inoculated goats, shown according to genotypes at codons 142, 154, 211, 222, and 240 of the *PRNP* gene<sup>a</sup>

Genotype	No. of clinically TSE-affected animals/total no. of animals	Scrapie incubation period (dpi) (mean ± SD)	Death from intercurrent disease		PrP <sup>Sc</sup> accumulation (no. of goats/total no. examined)	
			No. of goats/total no. in group	Time to death (dpi)	CNS	Lymphoid tissues <sup>b</sup>
I <sub>142</sub> R <sub>154</sub> R <sub>211</sub> Q <sub>222</sub> /IRRQ (wild type)	5/5	486 ± 21			5/5	5/5
M <sub>142</sub> RQ/IRRQ	5/5	788 ± 99			5/5	5/5
IH <sub>154</sub> RQ/IRRQ	5/5	624 ± 148			5/5	0/5
IRQ <sub>211</sub> Q/IRRQ	5/5	1,291 ± 325			5/5	5/5
IRQ <sub>211</sub> Q/IRRQ <sub>211</sub> Q	10/10	770 ± 139			10/10	1/10
IRRK <sub>222</sub> /IRRQ	2/5	1,900, 2,174	3/5	568, 898, 1,062	2/5 <sup>c</sup>	0/5
IRRK <sub>222</sub> /IRRK <sub>222</sub>	1/5	2,101			1/1	0/1

<sup>a</sup> Groups of five goats were intracerebrally challenged in the temporal cortex with the same classical scrapie isolate used for oral challenge. Animals that were still alive were at >2,400 days postinoculation at the time of writing.

<sup>b</sup> Tonsils, prescapular lymph nodes, ileal/jejunal Peyer's patches, and mesenteric lymph nodes.

<sup>c</sup> The two PrP<sup>Sc</sup>-positive animals were clinically affected.



**FIG 1** PrP<sup>Sc</sup> Western blot patterns for samples from the brains of goats intracerebrally challenged with a classical scrapie isolate. Ten percent tissue homogenates were prepared from brains of goats that had been intracerebrally challenged with a classical scrapie goat isolate and then developed the disease (Table 3). Abnormal PK-resistant PrP (PrP<sup>Sc</sup>) was detected following Western blotting using the Sha31 (YEDRYRE epitope) and 12B2 (WGQGG epitope) antibodies. In each gel, a classical scrapie sheep isolate (WB control) and the original isolate (orig. isolate) were used as controls.

signatures for i.c. challenged goats that harbored different genotypes suggests that different TSE agents propagated in those animals. However, it is our opinion that bioassays (which are currently ongoing) remain necessary before making conclusions on that point.

## DISCUSSION

Case-control studies of classical scrapie-affected herds (13–18) and limited data from experimental challenges (intracerebral routes) (19, 27) support the view that PrP K<sub>222</sub> allele goats might be strongly resistant to classical scrapie infection. Rare cases of the disease ( $n = 3$ ) were reported for heterozygous K<sub>222</sub> goats belonging to one single flock that displayed a high disease prevalence (27.4%), and no case has been reported so far for homozygous K<sub>222</sub> animals (14, 21).

Our study indicated that a classical scrapie isolate failed to

propagate in heterozygous K<sub>222</sub> goats following oral challenge. However, it also demonstrated that the same classical scrapie isolate could propagate in heterozygous and a proportion of homozygous K<sub>222</sub> animals following i.c. challenge, but with an incubation period that exceeded those observed in WT animals by 4 to 5 times.

These results for K<sub>222</sub> goats are very evocative of those obtained with A<sub>136</sub>R<sub>154</sub>R<sub>171</sub> allele sheep carriers that were naturally or experimentally exposed to TSE agents. After oral experimental challenge of homozygous and heterozygous ARR sheep, no or poorly efficient propagation of classical scrapie and BSE agents was observed (28–30). In heterozygous ARR sheep that were i.c. challenged with a classical scrapie agent, the disease occurred, but with significantly longer incubation periods than those in homozygous ARQ (wild-type *PRNP* genotype) sheep (30). Clinical TSEs occurred in a proportion of homozygous ARR sheep that were i.c. challenged with the cattle BSE agent, and the occurrence of rare natural classical scrapie cases was reported for animals harboring this genotype (31, 32).


All these results support the view that like the ARR allele in sheep, the K<sub>222</sub> allele is associated with high-level but not absolute resistance to scrapie.

For I/M<sub>142</sub> allele carriers, the i.c. and oral challenge results indicate that this allele is not associated with substantial resistance to the classical scrapie isolate we used. These observations are consistent with data collected from naturally infected goat herds (14, 21) and with the observations previously reported by Goldmann et al. for goats challenged with cattle BSE isolates, CH1641, and ME7 passaged in sheep (15).

No transmission or PrP<sup>Sc</sup> deposition could be observed in orally challenged heterozygous H<sub>154</sub> and Q<sub>211</sub> animals. However, a 100% attack rate was observed in animals bearing those genotypes following i.c. challenge, albeit with longer incubation periods than those in WT animals.

These results were similar to those observed in heterozygous K<sub>222</sub> animals. However, unlike homozygous K<sub>222</sub> goats, the homozygous Q<sub>211</sub> animals developed the disease with a 100% attack rate following i.c. challenge, with shorter incubation periods than those in heterozygous Q<sub>211</sub> animals. This indicates that the Q<sub>211</sub> allele cannot be considered to provide the same level of resistance against scrapie as the K<sub>222</sub> allele.

The lack of homozygous H<sub>154</sub> goats in the intracerebral inocu-



**FIG 2** PrP<sup>Sc</sup> glycoprofiles of the brains of goats intracerebrally challenged with a classical scrapie isolate. Ten percent tissue homogenates were prepared using posterior brain stems from goats that had been intracerebrally challenged with a classical scrapie goat isolate and then developed the disease (Table 3). Abnormal PK-resistant PrP (PrP<sup>Sc</sup>) was detected following Western blotting using the Sha31 antibody (YEDRYRE epitope). The signal volumes and relative percentages associated with monoglycosylated, biglycosylated, and unglycosylated bands were established using Quantity One software (Bio-Rad). Filled star, original isolate; ○, wild type; □, I/M<sub>142</sub>; ■, Q/K<sub>222</sub>; ◇, R/Q<sub>211</sub>; ◆, Q/Q<sub>211</sub>; ▽, H/R<sub>154</sub>.

lation experiment clearly limits our capacity to draw final conclusions concerning the level of resistance/susceptibility to classical scrapie associated with this *PRNP* allele. Nevertheless, the risk of atypical scrapie occurrence has been shown to be significantly higher in both H<sub>154</sub> allele carrier sheep and goats (the same PrP<sup>C</sup> sequence is present in goats and sheep) than in WT animals (7, 33). This higher level of susceptibility to atypical scrapie represents a major argument against the selection of the H<sub>154</sub> *PRNP* allele in goat populations.

Beyond this, the main limitation of this experiment is the fact that only one classical scrapie goat isolate was used to test the relative susceptibilities of the different genotypes. The diversity of TSE agents in small ruminants has been documented for several decades (26, 34, 35). In sheep, the susceptibility to TSE infection was shown to be influenced by both the nature of the TSE strain and the *PRNP* polymorphisms (36). Considering the time and resources necessary to carry out bioassays in large animals, testing of several classical scrapie agents in parallel in this model was simply not feasible. In this context, the inoculation of a variety of TSE agents into transgenic mice that express the WT and K<sub>222</sub> *PRNP* goat alleles will play a pivotal role in confirming the apparently low susceptibility/high resistance associated with the K<sub>222</sub> allele, and such work is reported in the accompanying article by Aguilar-Calvo et al. (37).

Finally, it should be noticed that the experimental approach we used allowed only estimations of the impact of individual *PRNP* polymorphisms on susceptibility to disease. For obvious material reasons, it was not possible to investigate the effects of *PRNP* haplotype combinations (such as individuals bearing both the Q<sub>211</sub> and K<sub>222</sub> alleles).

The development of *PRNP* genotype selection programs is now being considered by the European Union authorities as a potential tool to control and eradicate scrapie in commercial goat populations. In sheep, the diffusion of the ARR allele in the general population and, in particular, its introduction into classical scrapie-affected herds have proven its efficacy for the long-term control of the disease (10–12). The data that we report concur with the view that the K<sub>222</sub> allele in goats provides a level of resistance against scrapie infection similar to that seen with the ARR allele in sheep.

## ACKNOWLEDGMENTS

We thank Frédéric Bouvier and his team (INRA Domaine de la Sapinière) for producing goats with appropriate *PRNP* genotypes.

This work was funded by GIS PRION grant 31B06134, INRA grant AIP P00297, Poitou-Charentes Region grants 04/RPC-A-103 and 05/RPC-A-13, and the European Union (grants FOOD-CT-2006-36353 and 219235 FP7 ERA-NET EMIDA).

We declare no competing financial interests.

## REFERENCES

- Bolton DC, McKinley MP, Prusiner SB. 1982. Identification of a protein that purifies with the scrapie prion. *Science* 218:1309–1311. <http://dx.doi.org/10.1126/science.6815801>.
- Baylis M, Chihota C, Stevenson E, Goldmann W, Smith A, Sivam K, Tongue S, Gravenor MB. 2004. Risk of scrapie in British sheep of different prion protein genotype. *J. Gen. Virol.* 85:2735–2740. <http://dx.doi.org/10.1099/vir.0.79876-0>.
- Elsen JM, Amigues Y, Schelcher F, Ducrocq V, Andreoletti O, Eychenne F, Khang JV, Poivey JP, Lantier F, Laplanche JL. 1999. Genetic susceptibility and transmission factors in scrapie: detailed analysis of an epidemic in a closed flock of Romanov. *Arch. Virol.* 144:431–445. <http://dx.doi.org/10.1007/s007050050516>.
- Hunter N, Moore L, Hosie BD, Dingwall WS, Greig A. 1997. Association between natural scrapie and PrP genotype in a flock of Suffolk sheep in Scotland. *Vet. Rec.* 140:59–63. <http://dx.doi.org/10.1136/vr.140.3.59>.
- Benestad SL, Arzac JN, Goldmann W, Noremark M. 2008. Atypical/Nor98 scrapie: properties of the agent, genetics, and epidemiology. *Vet. Res.* 39:19. <http://dx.doi.org/10.1051/vetres:2007056>.
- Fediaevsky A, Maurella C, Noremark M, Ingravalle F, Thorgeirsdottir S, Orge L, Poizat R, Hautaniemi M, Liam B, Calavas D, Ru G, Hopp P. 2010. The prevalence of atypical scrapie in sheep from positive flocks is not higher than in the general sheep population in 11 European countries. *BMC Vet. Res.* 6:9. <http://dx.doi.org/10.1186/1746-6148-6-9>.
- Moreno CR, Moazami-Goudarzi K, Laurent P, Cazeau G, Andreoletti O, Chadi S, Elsen JM, Calavas D. 2007. Which PrP haplotypes in a French sheep population are the most susceptible to atypical scrapie? *Arch. Virol.* 152:1229–1232. <http://dx.doi.org/10.1007/s00705-007-0956-7>.
- Moum T, Olsaker I, Hopp P, Moldal T, Valheim M, Moum T, Benestad SL. 2005. Polymorphisms at codons 141 and 154 in the ovine prion protein gene are associated with scrapie Nor98 cases. *J. Gen. Virol.* 86:231–235. <http://dx.doi.org/10.1099/vir.0.80437-0>.
- Nodelijk G, van Roermund HJ, van Keulen LJ, Engel B, Vellema P, Hagenaars TJ. 2011. Breeding with resistant rams leads to rapid control of classical scrapie in affected sheep flocks. *Vet. Res.* 42:5. <http://dx.doi.org/10.1186/1297-9716-42-5>.
- Dawson M, Moore RC, Bishop SC. 2008. Progress and limits of PrP gene selection policy. *Vet. Res.* 39:25. <http://dx.doi.org/10.1051/vetres:2007064>.
- Fediaevsky A, Tongue SC, Noremark M, Calavas D, Ru G, Hopp P. 2008. A descriptive study of the prevalence of atypical and classical scrapie in sheep in 20 European countries. *BMC Vet. Res.* 4:19. <http://dx.doi.org/10.1186/1746-6148-4-19>.
- Hagenaars TJ, Melchior MB, Bossers A, Davidse A, Engel B, van Zijderveld FG. 2010. Scrapie prevalence in sheep of susceptible genotype is declining in a population subject to breeding for resistance. *BMC Vet. Res.* 6:25. <http://dx.doi.org/10.1186/1746-6148-6-25>.
- Acutis PL, Bossers A, Priem J, Riina MV, Peletto S, Mazza M, Casalone C, Forloni G, Ru G, Caramelli M. 2006. Identification of prion protein gene polymorphisms in goats from Italian scrapie outbreaks. *J. Gen. Virol.* 87:1029–1033. <http://dx.doi.org/10.1099/vir.0.81440-0>.
- Barillet F, Mariat D, Amigues Y, Faugeras R, Caillat H, Moazami-Goudarzi K, Rupp R, Babilliot JM, Lacroux C, Lukan S, Schelcher F, Chartier C, Corbiere F, Andreoletti O, Perrin-Chauvineau C. 2009. Identification of seven haplotypes of the caprine PrP gene at codons 127, 142, 154, 211, 222 and 240 in French Alpine and Saanen breeds and their association with classical scrapie. *J. Gen. Virol.* 90:769–776. <http://dx.doi.org/10.1099/vir.0.006114-0>.
- Goldmann W, Martin T, Foster J, Hughes S, Smith G, Hughes K, Dawson M, Hunter N. 1996. Novel polymorphisms in the caprine PrP gene: a codon 142 mutation associated with scrapie incubation period. *J. Gen. Virol.* 77:2885–2891. <http://dx.doi.org/10.1099/0022-1317-77-11-2885>.
- Papasavva-Stylianou P, Kleantous M, Toumazos P, Mavrikiou P, Loucaides P. 2007. Novel polymorphisms at codons 146 and 151 in the prion protein gene of Cyprus goats, and their association with natural scrapie. *Vet. J.* 173:459–462. <http://dx.doi.org/10.1016/j.tvjl.2005.09.013>.
- Papasavva-Stylianou P, Windl O, Saunders G, Mavrikiou P, Toumazos P, Kakoyiannis C. 2011. PrP gene polymorphisms in Cyprus goats and their association with resistance or susceptibility to natural scrapie. *Vet. J.* 187:245–250. <http://dx.doi.org/10.1016/j.tvjl.2009.10.015>.
- Vaccari G, Di Bari MA, Morelli L, Nonno R, Chiappini B, Antonucci G, Marcon S, Esposito E, Fazzi P, Palazzini N, Troiano P, Petrella A, Di Guardo G, Agrimi U. 2006. Identification of an allelic variant of the goat PrP gene associated with resistance to scrapie. *J. Gen. Virol.* 87:1395–1402. <http://dx.doi.org/10.1099/vir.0.81485-0>.
- Acutis PL, Martucci F, D'Angelo A, Peletto S, Colussi S, Maurella C, Porcario C, Iulini B, Mazza M, Dell'atti L, Zuccon F, Corona C, Martinelli N, Casalone C, Caramelli M, Lombardi G. 2012. Resistance to classical scrapie in experimentally challenged goats carrying mutation K222 of the prion protein gene. *Vet. Res.* 43:8. <http://dx.doi.org/10.1186/1297-9716-43-8>.
- Tabouret G, Lacroux C, Lukan S, Corbiere F, Weisbecker JL, Costes P, Schelcher F, Andreoletti O. 2010. Relevance of oral experimental challenge with classical scrapie in sheep. *J. Gen. Virol.* 91:2139–2144. <http://dx.doi.org/10.1099/vir.0.021311-0>.
- Corbiere F, Perrin-Chauvineau C, Lacroux C, Costes P, Thomas M, Bremaud I, Martin S, Lukan S, Chartier C, Schelcher F, Barillet F,

- Andreoletti O. 2013. PrP-associated resistance to scrapie in five highly infected goat herds. *J. Gen. Virol.* 94:241–245. <http://dx.doi.org/10.1099/vir.0.047225-0>.
22. Arsac JN, Andreoletti O, Bilheude JM, Lacroux C, Benestad SL, Baron T. 2007. Similar biochemical signatures and prion protein genotypes in atypical scrapie and Nor98 cases, France and Norway. *Emerg. Infect. Dis.* 13:58–65. <http://dx.doi.org/10.3201/eid1301.060393>.
  23. Lacroux C, Corbiere F, Tabouret G, Lugan S, Costes P, Mathey J, Delmas JM, Weisbecker JL, Foucras G, Cassard H, Elsen JM, Schelcher F, Andreoletti O. 2007. Dynamics and genetics of PrP<sup>Sc</sup> placental accumulation in sheep. *J. Gen. Virol.* 88:1056–1061. <http://dx.doi.org/10.1099/vir.0.82218-0>.
  24. Andreoletti O, Orge L, Benestad SL, Beringue V, Litaise C, Simon S, Le Dur A, Laude H, Simmons H, Lugan S, Corbiere F, Costes P, Morel N, Schelcher F, Lacroux C. 2011. Atypical/Nor98 scrapie infectivity in sheep peripheral tissues. *PLoS Pathog.* 7:e1001285. <http://dx.doi.org/10.1371/journal.ppat.1001285>.
  25. Feraudet C, Morel N, Simon S, Volland H, Frobert Y, Creminon C, Vilette D, Lehmann S, Grassi J. 2005. Screening of 145 anti-PrP monoclonal antibodies for their capacity to inhibit PrP<sup>Sc</sup> replication in infected cells. *J. Biol. Chem.* 280:11247–11258. <http://dx.doi.org/10.1074/jbc.M407006200>.
  26. Andreoletti O, Berthon P, Marc D, Sarradin P, Grosclaude J, van Keulen L, Schelcher F, Elsen JM, Lantier F. 2000. Early accumulation of PrP(Sc) in gut-associated lymphoid and nervous tissues of susceptible sheep from a Romanov flock with natural scrapie. *J. Gen. Virol.* 81:3115–3126. <http://vir.sgmjournals.org/content/81/12/3115.long>.
  27. White SN, Reynolds JO, Waldron DF, Schneider DA, O'Rourke KI. 2012. Extended scrapie incubation time in goats singly heterozygous for PRNP S146 or K222. *Gene* 501:49–51. <http://dx.doi.org/10.1016/j.gene.2012.03.068>.
  28. Andreoletti O, Morel N, Lacroux C, Rouillon V, Barc C, Tabouret G, Sarradin P, Berthon P, Bernardet P, Mathey J, Lugan S, Costes P, Corbiere F, Espinosa JC, Torres JM, Grassi J, Schelcher F, Lantier F. 2006. Bovine spongiform encephalopathy agent in spleen from an ARR/ARR orally exposed sheep. *J. Gen. Virol.* 87:1043–1046. <http://dx.doi.org/10.1099/vir.0.81318-0>.
  29. Foster JD, Parnham D, Chong A, Goldmann W, Hunter N. 2001. Clinical signs, histopathology and genetics of experimental transmission of BSE and natural scrapie to sheep and goats. *Vet. Rec.* 148:165–171. <http://dx.doi.org/10.1136/vr.148.6.165>.
  30. Goldmann W, Hunter N, Smith G, Foster J, Hope J. 1994. PrP genotype and agent effects in scrapie: change in allelic interaction with different isolates of agent in sheep, a natural host of scrapie. *J. Gen. Virol.* 75:989–995. <http://dx.doi.org/10.1099/0022-1317-75-5-989>.
  31. Groschup MH, Lacroux C, Buschmann A, Luhken G, Mathey J, Eiden M, Lugan S, Hoffmann C, Espinosa JC, Baron T, Torres JM, Erhardt G, Andreoletti O. 2007. Classic scrapie in sheep with the ARR/ARR prion genotype in Germany and France. *Emerg. Infect. Dis.* 13:1201–1207. <http://dx.doi.org/10.3201/eid1308.070077>.
  32. Houston F, Goldmann W, Chong A, Jeffrey M, Gonzalez L, Foster J, Parnham D, Hunter N. 2003. Prion diseases: BSE in sheep bred for resistance to infection. *Nature* 423:498. <http://dx.doi.org/10.1038/423498a>.
  33. Colussi S, Vaccari G, Maurella C, Bona C, Lorenzetti R, Troiano P, Casalnuovo F, Di Sarno A, Maniaci MG, Zuccon F, Nonno R, Casalone C, Mazza M, Ru G, Caramelli M, Agrimi U, Acutis PL. 2008. Histidine at codon 154 of the prion protein gene is a risk factor for Nor98 scrapie in goats. *J. Gen. Virol.* 89:3173–3176. <http://dx.doi.org/10.1099/vir.0.2008/004150-0>.
  34. Bruce ME, Boyle A, Cousens S, McConnell I, Foster J, Goldmann W, Fraser H. 2002. Strain characterization of natural sheep scrapie and comparison with BSE. *J. Gen. Virol.* 83:695–704. <http://vir.sgmjournals.org/content/83/3/695.long>.
  35. Pattison IH, Millson GC. 1962. Distribution of the scrapie agent in the tissues of experimentally inoculated goats. *J. Comp. Pathol.* 72:233–244.
  36. Beringue V, Vilotte JL, Laude H. 2008. Prion agent diversity and species barrier. *Vet. Res.* 39:47. <http://dx.doi.org/10.1051/vetres:2008024>.
  37. Aguilar-Calvo P, Espinosa JC, Pintado B, Gutiérrez-Adán A, Alamillo E, Miranda A, Prieto I, Bossers A, Andreoletti O, Torres JM. 2014. Role of the goat K<sub>222</sub>-PrP<sup>C</sup> polymorphic variant in prion infection resistance. *J. Virol.* 88:2670–2676. <http://dx.doi.org/10.1128/JVI.02074-13>.